MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y Xu-Monette, Alexander Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, Carlo Visco, Yong Li, Roberto N Miranda, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L Richards, Eric D Hsi, William W L Choi, Xiaoying ZhaoJ Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Ai, Maurilio Ponzoni, Andrés J M Ferreri, Fan Zhou, Graham W Slack, Randy D Gascoyne, Meifeng Tu, Daina Variakojis, Weina Chen, Ronald S Go, Miguel A Piris, Michael Møller, L Jeffrey Medeiros, Ken H Young

Research output: Contribution to journalJournal articleResearchpeer-review

437 Citations (Scopus)
Original languageEnglish
JournalBlood
Volume121
Issue number20
Pages (from-to)4021-31; quiz 4250
ISSN0006-4971
DOIs
Publication statusPublished - 16 May 2013

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • B-Lymphocyte Subsets
  • Cohort Studies
  • Cyclophosphamide
  • Doxorubicin
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • International Cooperation
  • Lymphocyte Activation
  • Lymphoma, Large B-Cell, Diffuse
  • Male
  • Middle Aged
  • Prednisone
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-myc
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis
  • Transcriptome
  • Vincristine

Fingerprint Dive into the research topics of 'MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program'. Together they form a unique fingerprint.

Cite this